Present and future of personalized medicine in adult genitourinary tumors

Chiara Ciccarese, Matteo Santoni, Francesco Massari, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, Alessandro Conti, Giampaolo Tortora, Stefano Cascinu, Rodolfo Montironi

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

The development of targeted agents has completely revolutionized the therapeutic scenario of genitourinary tumors. However, no biomarkers of tumor response or patient tolerability have been validated so far, and the selection of patients who may benefit from these approaches is still empirical. Significant advances in genomic sequencing and molecular characterization of these tumors have allowed identification of complex genomic abnormalities, thus increasing our knowledge on cancer biological landscapes and paving the way to the development of personalized strategies based on the patient's genomic and cancer's molecular profiles. This review is an overview of recent findings and emerging individualized therapies in patients with prostate, renal and bladder cancer, focusing on the promises and limitations of this approach in this setting.

Original languageEnglish (US)
Pages (from-to)1381-1388
Number of pages8
JournalFuture Oncology
Volume11
Issue number9
DOIs
StatePublished - May 1 2015

Keywords

  • bladder cancer
  • genitourinary tumors
  • personalized therapy
  • prostate cancer
  • renal cell carcinoma
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Present and future of personalized medicine in adult genitourinary tumors'. Together they form a unique fingerprint.

  • Cite this

    Ciccarese, C., Santoni, M., Massari, F., Cheng, L., Lopez-Beltran, A., Scarpelli, M., Conti, A., Tortora, G., Cascinu, S., & Montironi, R. (2015). Present and future of personalized medicine in adult genitourinary tumors. Future Oncology, 11(9), 1381-1388. https://doi.org/10.2217/fon.15.30